Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 30;11(9):2424.
doi: 10.3390/biomedicines11092424.

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Diego Bagnasco  1   2 , Stefania Nicola  3 , Elisa Testino  1   2 , Luisa Brussino  3 , Laura Pini  4 , Marco Caminati  5 , Federica Piccardo  2 , Rikki Frank Canevari  6 , Laura Melissari  1   2 , Alessandro Ioppi  6 , Luca Guastini  6 , Carlo Lombardi  7 , Manlio Milanese  8 , Francesca Losa  9 , Michela Robbiano  1   2 , Laura De Ferrari  1   2 , Anna Maria Riccio  1   2 , Giuseppe Guida  10 , Marco Bonavia  11 , Donatella Fini  12 , Francesco Balbi  13 , Cristiano Caruso  14 , Pierluigi Paggiaro  15 , Francesco Blasi  16   17 , Enrico Heffler  18   19 , Giovanni Paoletti  18   19 , Giorgio Walter Canonica  18   19 , Gianenrico Senna  5 , Giovanni Passalacqua  1   2 , On Behalf Of Sani
Affiliations

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders

Diego Bagnasco et al. Biomedicines. .

Abstract

The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (-84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting.

Keywords: CRSwNP; IL-5; eosinophils; mepolizumab; real life; registry; severe asthma.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Patients’ disposition during the 3 years of observation, with discontinuation rates and the reason of drug suspension. CRSwNP—Chronic rhinosinusitis with nasal polyps.
Figure 2
Figure 2
Main outcomes of the study. (A) Asthma exacerbations rate per year (Mean ± SD); (B) Oral corticosteroids (OCS) cumulative dose/y (g prednisolone) in steroid dependent patients; (C) Asthma Control Test (ACT) score; (D) Sinonasal Outcome Test (SNOT)-22 score (mean ± SD). *** p < 0.01; ** p < 0.05.
Figure 3
Figure 3
Comparison of exacerbation rates between our real-life cohort and Cosmos/Cosmex long-term trials.
See this image and copyright information in PMC

References

    1. Chiu C.-J., Huang M.-T. Asthma in the Precision Medicine Era: Biologics and Probiotics. Int. J. Mol. Sci. 2021;22:4528. doi: 10.3390/ijms22094528. - DOI - PMC - PubMed
    1. Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J., Adcock I.M., Bateman E.D., Bel E.H., Bleecker E.R., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2013;43:343–373. doi: 10.1183/09031936.00202013. - DOI - PubMed
    1. Kyriakopoulos C., Gogali A., Bartziokas K., Kostikas K. Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res. 2021;7 doi: 10.1183/23120541.00309-2020. - DOI - PMC - PubMed
    1. Bonato M., Bazzan E., Snijders D., Turato G., Turrin M., Cosio M.G., Barbato A., Saetta M., Baraldo S. Innate Lymphocytes -ILC2—Might Be the Drivers of T2-High Nonatopic Asthma in Children. Eur. Respir. J. 2021;58:PA861. doi: 10.1183/13993003.CONGRESS-2021.PA861. - DOI
    1. Fahy J.V. Type 2 Inflammation in Asthma-Present in Most, Absent in Many. Nat. Rev. Immunol. 2015;15:57–65. doi: 10.1038/nri3786. - DOI - PMC - PubMed